Compared to the placebo (n = 25), LBP supplementation relieved alanine transaminase (ALT) concentration and modulated gut dysbiosis in patients with NAFLD (n = 25) [50]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.